A Phase 3 interventional study of Herpes zoster vaccine GSK1437173A in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 1 site in Japan. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-25.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 41st largest by enrollment, is one of 4 that started in 2013, is one of 22 in phase 3, and was the 9th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2013.
This study's enrollment of 60 is below the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 35th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 3, and was the 17th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC) as compared to intramuscularly (IM) to people 50 years of age and older.
There are 2 treatment groups in this study based upon the mode of vaccine administration.
The humoral immunogenicity (HI) will be measured in all subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject, if female, of childbearing potential may be enrolled in the study, if the subject:
Chronic administration (defined as >14 consecutive days) of or other immune-modifying drugs within six months prior to the first vaccine dose.
Acute disease and/or fever at the time of vaccination:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
Biological: Herpes zoster vaccine GSK1437173A
Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
Biological: Herpes zoster vaccine GSK1437173A
HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)
A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value, of 18 mIU/mL.
Time frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
Anti-gE Antibody Concentrations
Anti-gE antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.
Time frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x18 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: At two months after Dose 1 (M2) and one month after Dose 2 (M3)
Descriptive Statistics of Anti-gE Antibody Concentrations
Anti-gE antibody concentrations were assessed by the Enzyme Lynked Immunosorbent Assay.
Time frame: Before vaccination (PRE), at two months after dose 1 (M2) and one month after Dose 2 (M3)
Number of Subjects With Solicited Local Symptoms
The solicited local symptoms assessed were: Arm movement/range of motion of the vaccinated arm, Injection site pruritus, Pain, Redness, and Swelling. Any = occurrence of any local symptom regardless of their intensity grade. Grade 3 Pain = Significant pain at rest that prevented normal every day activities. Grade 3 Injection site pruritus = Significant pruritus that prevented normal every day activities. Grade 3 impairment of arm movement/range of motion = Significant impairment of arm movement/range of motion that prevented normal every day activities.
Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were: Fatigue, Fever, Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), Headache, Myalgia, and Shivering. Fever = axillary temperature ≥37.5°C. Any = occurrence of any general symptoms regardless of their intensity grade or relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Fever = axillary temperature higher than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to vaccination.
Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
Mean Number of Days With Local Symptoms
Days with solicited local symptoms were tabulated for the total vaccinated cohort.
Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)
Mean Number of Days With General Symptoms
Days with solicited general symptoms were tabulated for the total vaccinated cohort.
Time frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)
Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)
Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: From Month 0 to Month 3
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days (Days 0-29) post vaccination period
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 to Month 3
Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL
A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value of 97 mIU/mL.
Time frame: At Month 14
Anti-gE Antibody Concentrations
Anti-gE antibody concentrations were expressed as geometric mean concnetrations (GMCs) and measured in mIU/mL.
Time frame: At Month 14
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: Twelve Months after Dose 2 (M14)
Number of Subjects With pIMDs
Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Time frame: Up to Month 14 post vaccination period
Number of Subjects With SAEs
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: Up to Month 14 post vaccination period
| Milestone | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 29 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value, of 18 mIU/mL.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Anti-gE, PRE | 29 | 29 |
| Anti-gE, M2 | 29 | 29 |
| Anti-gE, M3 | 29 | 29 |
Anti-gE antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.
| mIU/mL | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Anti-gE, PRE | 1424.3 (1042.6 to 1945.6) | 1116.8 (774.5 to 1610.3) |
| Anti-gE, M2 | 19902.5 (14846.9 to 26679.6) | 12842 (8558.4 to 19269.7) |
| Anti-gE, M3 | 44126.1 (36326.1 to 53601) | 45521.5 (37549.5 to 55185.9) |
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x18 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Anti-gE, M2 | 28 | 25 |
| Anti-gE, M3 | 29 | 29 |
Anti-gE antibody concentrations were assessed by the Enzyme Lynked Immunosorbent Assay.
| mIU/mL | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Anti-gE, PRE | 1404.1 ± 1398.82 | 946.3 ± 3231.78 |
| Anti-gE, M2 | 19400.1 ± 24456.86 | 14330.1 ± 14548.75 |
| Anti-gE, M3 | 44182 ± 27990.99 | 42444.8 ± 27555.21 |
The solicited local symptoms assessed were: Arm movement/range of motion of the vaccinated arm, Injection site pruritus, Pain, Redness, and Swelling. Any = occurrence of any local symptom regardless of their intensity grade. Grade 3 Pain = Significant pain at rest that prevented normal every day activities. Grade 3 Injection site pruritus = Significant pruritus that prevented normal every day activities. Grade 3 impairment of arm movement/range of motion = Significant impairment of arm movement/range of motion that prevented normal every day activities.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Any Arm movement impairment, D1 | 10 | 7 |
| Any Arm movement impairment, D2 | 16 | 11 |
| Any Arm movement impairment, Across | 18 | 12 |
| Grade 3 Arm movement impairment, D1 | 1 | 0 |
| Grade 3 Arm movement impairment, D2 | 0 | 0 |
| Grade 3 Arm movement impairment, Across | 1 | 0 |
| Any Injection site pruritus, D1 | 19 | 6 |
| Any Injection site pruritus, D2 | 15 | 8 |
| Any Injection site pruritus, Across | 21 | 10 |
| Grade 3 Injection site pruritus, D1 | 0 | 0 |
| Grade 3 Injection site pruritus, D2 | 0 | 0 |
| Grade 3 Injection site pruritus, Across | 0 | 0 |
| Any Pain, D1 | 28 | 26 |
| Any Pain, D2 | 25 | 21 |
| Any Pain, Across | 28 | 27 |
| Grade 3 Pain, D1 | 2 | 0 |
| Grade 3 Pain, D2 | 1 | 0 |
| Grade 3 Pain, Across | 2 | 0 |
| Any Redness, D1 | 23 | 11 |
| Any Redness, D2 | 23 | 12 |
| Any Redness, Across | 26 | 15 |
| Grade 3 Redness, D1 | 12 | 1 |
| Grade 3 Redness, D2 | 12 | 1 |
| Grade 3 Redness, Across | 17 | 2 |
| Any Swelling, D1 | 22 | 7 |
| Any Swelling, D2 | 20 | 11 |
| Any Swelling, Across | 24 | 12 |
| Grade 3 Swelling, D1 | 8 | 1 |
| Grade 3 Swelling, D2 | 6 | 1 |
| Grade 3 Swelling, Across | 10 | 2 |
Assessed solicited general symptoms were: Fatigue, Fever, Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), Headache, Myalgia, and Shivering. Fever = axillary temperature ≥37.5°C. Any = occurrence of any general symptoms regardless of their intensity grade or relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Fever = axillary temperature higher than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to vaccination.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Any Fatigue, D1 | 14 | 12 |
| Any Fatigue, D2 | 16 | 9 |
| Any Fatigue, Across | 21 | 16 |
| Grade 3 Fatigue, D1 | 0 | 0 |
| Grade 3 Fatigue, D2 | 0 | 1 |
| Grade 3 Fatigue, Across | 0 | 1 |
| Related Fatigue, D1 | 14 | 12 |
| Related Fatigue, D2 | 16 | 9 |
| Related Fatigue, Across | 21 | 16 |
| Any Fever/Axillary, D1 | 3 | 2 |
| Any Fever/Axillary, D2 | 5 | 6 |
| Any Fever/Axillary, Across | 6 | 7 |
| Grade 3 Fever/Axillary, D1 | 0 | 0 |
| Grade 3 Fever/Axillary, D2 | 0 | 0 |
| Grade 3 Fever/Axillary, Across | 0 | 0 |
| Related Fever/Axillary, D1 | 3 | 2 |
| Related Fever/Axillary, D2 | 5 | 6 |
| Related Fever/Axillary, Across | 6 | 7 |
| Any Gastrointestinal symptoms, D1 | 2 | 4 |
| Any Gastrointestinal symptoms, D2 | 5 | 3 |
| Any Gastrointestinal symptoms, Across | 7 | 5 |
| Grade 3 Gastrointestinal symptoms, D1 | 0 | 0 |
| Grade 3 Gastrointestinal symptoms, D2 | 0 | 1 |
| Grade 3 Gastrointestinal symptoms,Across | 0 | 1 |
| Related Gastrointestinal symptoms, D1 | 2 | 4 |
| Related Gastrointestinal symptoms, D2 | 5 | 3 |
| Related Gastrointestinal symptoms,Across | 7 | 5 |
| Any Headache, D1 | 11 | 8 |
| Any Headache, D2 | 11 | 10 |
| Any Headache, Across | 17 | 13 |
| Grade 3 Headache, D1 | 0 | 0 |
| Grade 3 Headache, D2 | 0 | 2 |
| Grade 3 Headache, Across | 0 | 2 |
| Related Headache, D1 | 11 | 8 |
| Related Headache, D2 | 11 | 10 |
| Related Headache, Across | 17 | 13 |
| Any Myalgia, D1 | 2 | 1 |
| Any Myalgia, D2 | 5 | 3 |
| Any Myalgia, Across | 7 | 4 |
| Grade 3 Myalgia, D1 | 1 | 0 |
| Grade 3 Myalgia, D2 | 0 | 1 |
| Grade 3 Myalgia, Across | 1 | 1 |
| Related Myalgia, D1 | 2 | 1 |
| Related Myalgia, D2 | 5 | 3 |
| Related Myalgia, Across | 7 | 4 |
| Any Shivering, D1 | 3 | 3 |
| Any Shivering, D2 | 6 | 6 |
| Any Shivering, Across | 8 | 7 |
| Grade 3 Shivering, D1 | 0 | 1 |
| Grade 3 Shivering, D2 | 0 | 0 |
| Grade 3 Shivering, Across | 0 | 1 |
| Related Shivering, D1 | 3 | 3 |
| Related Shivering, D2 | 6 | 6 |
| Related Shivering, Across | 8 | 7 |
Days with solicited local symptoms were tabulated for the total vaccinated cohort.
| Days | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Days with arm movement, D1 | 3.9 (2 to 7) | 3 (2 to 3) |
| Days with pain, D1 | 3.3 (2 to 4) | 2.7 (2 to 3) |
| Days with injection site pruritus, D1 | 5.2 (2 to 7) | 2.2 (1 to 3) |
| Days with redness, D1 | 6.5 (4 to 8) | 2.6 (2 to 3) |
| Days with swelling, D1 | 5 (3 to 6) | 3 (2 to 3) |
| Days with arm movement, D2 | 2.9 (2 to 3) | 2.2 (2 to 3) |
| Days with pain, D2 | 3.4 (2 to 4) | 2.3 (1 to 3) |
| Days with injection site pruritus, D2 | 4.9 (3 to 5) | 1.9 (1.5 to 2) |
| Days with redness, D2 | 5.9 (3 to 6) | 3.7 (3 to 4) |
| Days with swelling, D2 | 4.3 (3 to 6) | 2.8 (2 to 4) |
Days with solicited general symptoms were tabulated for the total vaccinated cohort.
| Days | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Days with fatigue, D1 | 2.3 (1 to 3) | 2 (1 to 2) |
| Days with fever, D1 | 1.3 (1 to 2) | 1 (1 to 1) |
| Days with gastrointestinal symptoms, D1 | 2 (1 to 3) | 2 (2 to 2) |
| Days with headache, D1 | 1.8 (1 to 2) | 1.4 (1 to 2) |
| Days with myalgia, D1 | 6.5 (3 to 10) | 2 (2 to 2) |
| Days with Shivering, D1 | 1.3 (1 to 2) | 1.3 (1 to 2) |
| Days with fatigue, D2 | 2 (1 to 2) | 1.3 (1 to 2) |
| Days with fever, D2 | 1 (1 to 1) | 1 (1 to 1) |
| Days with gastrointestinal symptoms, D2 | 3.6 (2 to 5) | 1.3 (1 to 2) |
| Days with headache, D2 | 2 (1 to 2) | 1.3 (1 to 2) |
| Days with myalgia, D2 | 2 (1 to 2) | 1.3 (1 to 2) |
| Days with Shivering, D2 | 2.2 (1 to 2.2) | 1 (1 to 1) |
Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With Potential Immune-Mediated Disorders (pIMDs) | 0 | 0 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Any AEs | 9 | 6 |
| Grade 3 AEs | 1 | 0 |
| Related AEs | 1 | 1 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 1 | 0 |
A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value of 97 mIU/mL.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL | 30 | 28 |
Anti-gE antibody concentrations were expressed as geometric mean concnetrations (GMCs) and measured in mIU/mL.
| mIU/mL | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Anti-gE Antibody Concentrations | 15250.9 (12464 to 18660.9) | 13870.2 (10184.2 to 18890.3) |
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations | 25 | 25 |
Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With pIMDs | 0 | 0 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Number of Subjects With SAEs | 2 | 1 |
Collected over Solicited symptoms: during the 7-day post-vaccination period; Unsolicited AEs: during the 30-day post-vaccination period; SAEs: up to Month 14 post vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SC GSK1437173A Group | 0/30 (0%) | 2/30 (6.7%) | 30/30 (100%) |
| IM GSK1437173A Group | 0/30 (0%) | 1/30 (3.3%) | 28/30 (93.3%) |
| Event | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| Spinal compression fractureInjury, poisoning and procedural complications | 0/30 | 1/30 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/30 | 0/30 |
| Mallet fingerMusculoskeletal and connective tissue disorders | 1/30 | 0/30 |
| Event | SC GSK1437173A Group | IM GSK1437173A Group |
|---|---|---|
| PainGeneral disorders | 28/30 | 27/30 |
| RednessGeneral disorders | 26/30 | 15/30 |
| SwellingGeneral disorders | 24/30 | 12/30 |
| Injection site pruritusGeneral disorders | 21/30 | 10/30 |
| FatigueGeneral disorders | 21/30 | 16/30 |
| Arm movementGeneral disorders | 18/30 | 12/30 |
| HeadacheGeneral disorders | 17/30 | 13/30 |
| ShiveringGeneral disorders | 8/30 | 7/30 |
| Fever/(Axillary)General disorders | 6/30 | 7/30 |
| Gastrointestinal symptomsGeneral disorders | 7/30 | 5/30 |
| Age, Continuous(Years) | SC GSK1437173A Group | IM GSK1437173A Group | Total |
|---|---|---|---|
| Mean | 61.6 ± 7.59 | 62.2 ± 7.83 | 61.90 ± 7.65 |
| Sex: Female, Male(Participants) | SC GSK1437173A Group | IM GSK1437173A Group | Total |
|---|---|---|---|
| Female | 15 | 15 | 30 |
| Male | 15 | 15 | 30 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jun 2013, a primary completion of Oct 2013 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 3 years 2 months after primary completion. A results delay was requested in Dec 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix